Neurodegenerative Disease Archives · BioBuzz

Loading …

Clene Nanomedicine Aims to be the ‘Gold Standard’ in Neurodegenerative Disease

<img width="300" height="300" alt="" data-srcset="https://biobuzz.io/wp-content/uploads/2021/01/Clene-Featured-300x300.png 300w, https://biobuzz.io/wp-content/uploads/2021/01/Clene-Featured-150x150.png 150w, https://biobuzz.io/wp-content/uploads/2021/01/Clene-Featured-75x75.png 75w" data-src="https://biobuzz.io/wp-content/uploads/2021/01/Clene-Featured-300x300.png" data-sizes="(max-width: 300px) 100vw, 300px" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="300" height="300" src="https://biobuzz.io/wp-content/uploads/2021/01/Clene-Featured-300x300.png" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload" alt="" srcset="https://biobuzz.io/wp-content/uploads/2021/01/Clene-Featured-300x300.png 300w, https://biobuzz.io/wp-content/uploads/2021/01/Clene-Featured-150x150.png 150w, https://biobuzz.io/wp-content/uploads/2021/01/Clene-Featured-75x75.png 75w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : January 19, 2021January 19, 2021 Published by : Alex Keown

Clene Nanomedicine, one of Maryland’s Future 2020 companies, closed a merger with Tottenham Acquisition I Limited that provided the company with a slot on the Nasdaq Exchange and $3.19 million that will be used to advance the company’s gold nanocrystal-based treatment for neurodegenerative diseases.